Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Allergy TherapeuticsLSE:AGY +1.19% EV-to-FCF is -12.01 as of Jul. 14, 2026. The stock has 7 warning signs investors should review. Among 562 Drug Manufacturers companies, Allergy Therapeutics ranks worse than 177935.77% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Allergy Therapeutics's Enterprise Value is £447.28 Mil.
Allergy Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £-37.25 Mil. Therefore, Allergy Therapeutics's EV-to-FCF for today is -12.01.
The historical rank and industry rank for Allergy Therapeutics's EV-to-FCF or its related term are showing as below:
LSE:AGY'
s EV-to-FCF Range Over the Past 10 Years
Min: -132.27 Med: -6.07 Max: 37.87
Current: -11.87
During the past 13 years, the highest EV-to-FCF of Allergy Therapeutics was 37.87. The lowest was -132.27. And the median was -6.07.
LSE:AGY's EV-to-FCF is ranked worse than 100% of 562
companies
in the Drug Manufacturers industry
Industry Median: 21.055
vs LSE:AGY: -11.87
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Allergy Therapeutics's PE Ratio (TTM) for today is calculated as:
Allergy Therapeutics's share price for today is £0.068.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was £-0.010.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Allergy Therapeutics EV-to-FCF Related Terms
Allergy Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Allergy Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Allergy Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Allergy Therapeutics EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Allergy Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Allergy Therapeutics's EV-to-FCF falls into.
Allergy Therapeutics's current Enterprise Value is £447.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Allergy Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was £-37.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Allergy Therapeutics (LSE:AGY) has a EV-to-FCF of -12.01 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Allergy Therapeutics and its competitors. According to the industry distribution chart, Allergy Therapeutics ranks #999999 out of 562 companies in the Drug Manufacturers industry.
Is Allergy Therapeutics' EV-to-FCF too high?
Allergy Therapeutics' current EV-to-FCF is -12.01. Based on the distribution chart, Allergy Therapeutics ranks #999999 out of 562 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Allergy Therapeutics' EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Allergy Therapeutics ranks #999999 out of 562 companies for EV-to-FCF. This places Allergy Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 21.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.06, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Allergy Therapeutics and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Allergy Therapeutics's current EV-to-FCF is -12.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (LSE:AGY) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.03, compared to a current price of £0.07 — trading 126.7% above its estimated fair value. The current EV-to-FCF is -12.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Allergy Therapeutics (LSE:AGY), the current EV-to-FCF is -12.01 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:AGY has been successfully added to your 
